ASMB Assembly Biosciences Inc

Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that John McHutchison, AO, MD, Chief Executive Officer and President will make a corporate presentation at the Jefferies London Healthcare Conference on Wednesday, November 20, 2019 at 9:20am GMT.

A live webcast and replay of the Jefferies presentation will be available in the Events & Presentations page in the Investors section of the company's website at assemblybio.com.  

About Assembly Biosciences Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly’s fully integrated platform, including a robust process for strain identification and selection, GMP-compliant banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. For more information, visit assemblybio.com.

Contacts Assembly Biosciences, Inc. Investors: Lauren Glaser (415) 521-3828 lglaser@assemblybio.com